CMPX · Compass Therapeutics Inc
United States · RS rating 6 · As of 2026-11-03
| Price | 0.75 USD |
|---|---|
| 1-day change | -1.9% |
| RS rating (overall / 1M / 3M / 12M) | 6 / 20 / 6 / 9 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 25 / 6 / 28 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -12.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +88.7% |
| Market cap (USD) | $938.3M |